Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2005

View Archived Issues

Schering-Plough highlights first quarter developments

G-207 studied in malignant glioma

NX-1207 shows long-term efficacy in improving the symptoms of BPH

Phase II study investigates ginger for CINV

Dosing begins in phase I trial of Hedgehog antagonist for basal cell carcinoma

Harnal D launched in Japan

Chugai subsidiary renamed

FDA extends action date for SomatoKine NDA

MicroRNAs: potential novel human oncogenes

Further study required for Sativex approval in U.K.

IPI-504 studied in relapsed and relapsed refractory multiple myeloma

Spotlight on PTSD

Phase I results discussed for Sinovac's SARS vaccine

Fast track designation for Laszarin for heart failure in diabetes patients

NIP-004: Novel thrombopoietin mimetic small-molecule compound

Combi-molecule targets Bcr-Abl kinase and damages DNA

Lyrica approved as add-on treatment for partial onset seizures

Zmax single-dose antibiotic receives FDA approval

Long-term effects reported for febuxostat in hyperuricemia and gout

Clazosentan acts as a potent competitive ETA receptor antagonist

NVP-AEW-541 studied for treatment of musculoskeletal tumors

Recent patent discloses novel immunosuppressive agents

Iloprost and bosentan reduce mortality in PPH patients waiting for a transplant

Novel therapeutics for cardiovascular diseases reported in recent patents

Potassium channel blockers for glaucoma, etc., emerge from Merck & Co. research

MCI-196 decreases serum phosphate and cholesterol levels of hemodialysis patients